Oncolytics Biotech Inc. (Form 6-K Summary)

This Form 6-K, filed November 4, 2025, primarily serves to incorporate an attached Exhibit 99.1, which is a Press Release.

• Key Event: Investors must review Exhibit 99.1 for material disclosures.
• Financial/Management: The filing is signed by CFO Kirk Look. No specific financial metrics or guidance are detailed on the cover sheet.
• Regulatory Note: Oncolytics confirms filing annual reports on Form 20-F.

Critical Action: Review the linked Press Release (Exhibit 99.1) for substantive business updates, strategi